SkinBioTherapeutics plc - Full Year Results
October 05 2017 - 1:02AM
Business Wire
SkinBioTherapeutics plc (AIM: SBTX or the “Company”) a life
sciences company focused on skin health, has announced its full
year results for the year to 30 June 2017.
Key highlights
- Research agreement with the University
of Manchester for ‘development of a bacterial lysate as a novel
agent to combat infections’
- Successful demonstration of the three
modes of action of the SkinBiotix® technology
- Creating a strong Board and management
team for the development and commercial phase of the Company
- Admission to AIM in April 2017 raising
£4.5m
- Initiating scale up of lysate
manufacture with third parties
- Cash as at 30 June 2017 £3.9m (2016:
£0.3m)
- Post year end: SkinBiotix® passed
cytotoxicity test, representing first key milestone post IPO
Cath O’Neill, CEO of SkinBioTherapeutics, said:
“This has been a significant year for the Company; from creating
the infrastructure and team to support the growth and development
of the Company, to the scientific progress around our proprietary
skin platform, SkinBiotix®.
“During the year, we have demonstrated three significant
properties – barrier improvement, anti-infection and repair – which
form the foundations of our three development programmes. We are
making good scientific headway and are starting initial discussions
with partners.
“Operationally, we have made a good start to the new financial
year, especially with the recent news around the third party
cytotoxicity testing, and we look forward to reporting on the next
phase of the Company’s journey.”
The information communicated within this announcement is deemed
to constitute inside information as stipulated under the Market
Abuse Regulations (EU) No. 596/2014. Upon the publication of this
announcement, this inside information is now considered to be in
the public domain.
-Ends-
For the full announcement
visit www.skinbiotherapeutics.com
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin
health. The Company’s proprietary platform technology, SkinBiotix®,
is based upon discoveries made by CEO Dr. Catherine O’Neill and
Professor Andrew McBain.
SkinBioTherapeutics’ platform applies research discoveries made
on the activities of lysates derived from probiotic bacteria when
applied to the skin. The Company has shown that the SkinBiotix®
platform can improve the barrier effect of skin models, protect
skin models from infection and repair skin models. Proof of
principle studies have shown that the SkinBiotix® platform has
beneficial attributes applicable to each of these areas.
SkinBioTherapeutics received seed funding from the Tech Transfer
office of the University of Manchester for the discovery of
SkinBiotix®. The platform was subsequently spun out of the
University of Manchester in March 2016 and was funded by OptiBiotix
(AIM: OPTI).
The Company joined AIM in April 2017 concurrent with raising
£4.5 million from a placing of new ordinary shares.
The Company is based in Manchester, UK. For more information,
visit www.skinbiotherapeutics.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171004006379/en/
For more information, please
contact:SkinBioTherapeutics plcTel: +44 (0) 161 468
2760Dr. Cath O’Neill, CEODoug Quinn, CFOorCairn Financial
Advisers LLPTel: +44 (0) 20 7213 0880Tony Rawlinson /
Emma Earl / Richard NashorTurner Pope InvestmentsTel: +44
(0) 20 3621 4120Ben Turner / James PopeorInstinctif
PartnersMelanie Toyne-Sewell / Deborah BellTel: +44 (0) 20
7457 2020SkinBio@instinctif.com
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Apr 2024 to May 2024
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From May 2023 to May 2024